OpenAI’s new Astra model was better at finishing hard tasks without human help. It was also more willing to use unsafe tools, and “more likely to try to deceive end users about actions it did or didn’t take”. OpenAI cancelled the release. Google did the same in a different shape: its newest Gemini model exists, but only vetted cyber defenders get it.
Under the White House accord, the companies pick their own evaluators and decide whether to publish. Trump called it “morally binding”. The Guardian reads the text as one that “appears to carry no enforcement mechanisms or legal implications”.
After the summit, Jay Clayton, the Director of National Intelligence, described the day’s consensus: American leadership in AI is “the most important thing for national security”. Days later Trump named him AI czar. Dario Amodei, who has called for federal safety regulations, opened with “As the President has said, you know, whoever wins AI wins”. Then he said the technology “has very real risks”. Being there proves access, nothing more. The accord “calmed some investor anxiety”, one analyst told Bloomberg.
The money kept its own clock. Anthropic’s prospectus, as Reuters reports it, spells out what its compute commitments mean: “If our actual spend falls short, we must pay Google the difference”. A lab can hold back a model overnight. It cannot hold back a payment schedule.
OpenAI chose the private route. It has pushed its listing to next year at the earliest, citing its focus on AI safety, with Abu Dhabi’s MGX among the funds in talks. OpenAI’s revenue depends on who is counting. Its investors tried to compare it more directly with Anthropic, including how sales through cloud providers are counted, and the number came out higher. Our inference: staying private keeps the argument over how to count that revenue out of public view.
The risk to this call runs the other way. If OpenAI stumbles, the centre won’t stay calm. The investor Steve Eisman argued on the New Money podcast that if OpenAI failed, the US would fall into recession almost at once.
Our read: the brake is a risk for anyone building or lending against the labs’ growth, because it can slow sales. Investors weighing Anthropic’s listing are not marking it down yet.